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Omiganan Enhances Imiquimod-Induced Inflammatory 
Responses in Skin of Healthy Volunteers
Tessa Niemeyer-van der Kolk1,†, Salma Assil1,†, Thomas P. Buters1, Melanie Rijsbergen1, Erica S. Klaassen1 , Gary Feiss2, 
Edwin Florencia3, Errol P. Prens3, Jacobus Burggraaf1,4,5, Martijn B.A. van Doorn3, Robert Rissmann1,4,5,* and Matthijs Moerland1
Omiganan (OMN; a synthetic cationic peptide) and imiquimod (IMQ; a TLR7 agonist) have synergistic effects on interferon re-
sponses in vitro. The objective of this study was to translate this to a human model for proof-of-concept, and to explore the po-
tential of OMN add-on treatment for viral skin diseases. Sixteen healthy volunteers received topical IMQ, OMN, or a combination of 
both for up to 4 days on tape-stripped skin. Skin inflammation was quantified by laser speckle contrast imaging and 2D photog-
raphy, and molecular and cellular responses were analyzed in biopsies. IMQ treatment induced an inflammatory response of the 
skin. Co-treatment with OMN enhanced this inflammatory response to IMQ, with increases in perfusion (+17.1%; 95% confidence 
interval (CI) 5.6%–30%; P < 0.01) and erythema (+1.5; 95% CI 0.25%–2.83; P = 0.02). Interferon regulatory factor-driven and NFκB-
driven responses following TLR7 stimulation were enhanced by OMN (increases in IL-6, IL-10, MXA, and IFNɣ), and more immune 
cell infiltration was observed (in particular CD4+, CD8+, and CD14+ cells). These findings are in line with the earlier mechanistic 
in vitro data, and support evaluation of imiquimod/OMN combination therapy in human papillomavirus-induced skin diseases.
Cathelicidins are a family of antimicrobial (cationic) peptides 
that play an important role in the first line immune defense of 
the skin, related to their broad antimicrobial activity against 
bacteria, viruses, and fungi.1 LL-37 is the only human mem-
ber of the cathelicidin family.1 Besides its antimicrobial 
effects, this peptide also has direct immunomodulatory ac-
tivity. LL-37 affects the response of neutrophils to viruses, 
and modulates interferon (IFN) responses induced by viral 
triggers.2 LL-37 converts self-RNA into a ligand for toll-like 
receptor (TLR)7 and TLR8 in human dendritic cells, thereby 
enhancing IFNα production in human skin.3
Omiganan (OMN) is a synthetic indolicidin (a cathe-
licidin isolated from bovine neutrophils), currently under 
development as topical gel for several clinical indications. 
OMN is known to have activity against a wide variety 
of microorganisms, such as gram-positive and gram- 
negative bacteria and fungi.4,5 Moreover, OMN enhances 
IFN responses induced by TLR3 (Poly:IC), TLR7 (imiqui-
mod (IMQ)), TLR8 (ssRNA), and TLR9 (CpG) in human 
immune cells, comparable but not similar to the effects 
observed for LL-37 (unpublished data, Grievink et al.). 
These observations support the future application of OMN 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Omiganan (OMN) enhances IFN responses induced by 
TLR7 (imiquimod (IMQ)) in vitro, which supports the future 
application of OMN as co-treatment with IMQ for viral skin 
disease in humans.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  Does OMN treatment enhance IMQ-induced IFN re-
sponses in the IMQ skin inflammation challenge model in 
healthy volunteers?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔OMN enhanced the inflammatory skin response to 
IMQ, supporting evaluation of IMQ/OMN combination 
therapy in HPV-induced skin diseases, such as ano-
genital warts or high-grade squamous intraepithelial 
lesion.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
✔  This study shows that the IMQ skin inflammation chal-
lenge model is suitable to study proof-of-pharmacology of 
novel compounds targeting the innate immune system in 
healthy volunteers.
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as co-treatment with endosomal TLR ligands for viral skin 
disease in humans.
IMQ is the only registered endosomal TLR ligand, as 
Aldara topical cream. The mechanism of action of IMQ is 
based on TLR7-dependent MyD88-signaling.6,7 This re-
sults in two responses: a tumoricidal effect by the release 
of several pro-inflammatory cytokines (e.g., TNF-α, IL-6, 
and IL-8, via NFκB) and an antiviral response by the in-
duction of IFNα and IFN-inducible genes (e.g., MX1 and 
MXA, via interferon regulatory factor (IRF)7).8 Based on 
these mechanisms IMQ is widely used in clinical prac-
tice for human papillomavirus (HPV)-induced anogenital 
warts and high-grade squamous intraepithelial lesions of 
the vulva (vulvar HSIL), actinic keratosis, and basal cell 
carcinoma.9 In most of these conditions, drug efficacy 
is suboptimal, and lesions may re-occur after treatment 
discontinuation.10 Therefore, a treatment enhancing the ef-
ficacy of IMQ in these dermatological conditions would be 
of great benefit. Based on its observed preclinical activity, 
OMN may be a good candidate for combination treatment 
with IMQ.
We recently developed an in vivo challenge model with 
transient local skin inflammation, induced by 48 hours IMQ 
(Aldara cream, Aldara, Meda Pharma, Solna, Sweden) ap-
plication under occlusion by a 12  mm Finn chamber to 
tape-stripped skin.11 This model was used in the current 
study to explore the potential of combined IMQ and OMN 
treatment as novel therapeutic modality for HPV-induced 
skin diseases (e.g., genital warts and vulvar HSIL). OMN was 
applied topically to IMQ-primed skin, and the clinical, bio-
physical, cellular, and molecular responses to this combined 
treatment were investigated.
METHODS
Study design and subjects
This was a randomized, open-label, evaluator-blinded, 
vehicle-controlled, parallel-cohort, dose-ranging study. 
The study was conducted from February 2017 to March 
2017 at the Centre for Human Drug Research, Leiden, 
The Netherlands, and was approved by the indepen-
dent Medical Ethics Committee “Medisch Ethische 
Toetsingscommissie van de Stichting Beoordeling Ethiek 
Biomedisch Onderzoek” (Assen, The Netherlands). The 
study was conducted according to the Dutch Act on 
Medical Research involving Human Subjects (WMO). 
Before study procedures started, all subjects gave in-
formed consent. Sixteen healthy male and female white 
(Fitzpatrick skin type III) volunteers, aged 18–45  years, 
were included. Subjects with a (family) history of psoriasis 
or any disease associated with immune system impair-
ment were excluded.
Treatments and randomization
To explore the effect of OMN and the combination of 
OMN and IMQ on tape-stripped skin, treatment com-
binations were applied and randomized over different 
treatment sites on the back (Table 1). All four treatment 
combinations were explored in each study participant. A 
standard daily dosage containing either 100  mg Aldara 
5% (5  mg IMQ), 100  mg OMN 1% (1  mgOMN), 100  mg 
OMN 2.5%, 100 mg OMN vehicle (VehO), or cetomacrogol 
(which served as IMQ vehicle (VehI)) was applied under 
occlusion by a 12  mm Finn chamber (Smart Practice, 
Phoenix, AZ). The tape-stripping procedure included 20 
times stripping with tape (D-Squame; CuDerm, Dallas, 
TX) to induce mild barrier disruption.
It should be noted that within the same clinical study, 
alternative regimens and control conditions were explored 
within the same group of 16 volunteers. These additional 
conditions included the reverse treatment sequence (first 
IMQ, then OMN) and partial control groups VehI or VehO 
(1% or 2.5%). To increase the readability of this paper, it 
was decided to not present data related to these conditions.
Skin assessments
The skin was assessed daily for 5 days for signs of inflam-
mation (erythema and hyperperfusion) by 2D photography, 
erythema index analysis, visual erythema grading (Clinician 
Erythema Assessment (CEA) scale; 0 represents absence 
of erythema, 4 very severe), colorimetry (a* value; DSM 
II ColorMeter; Cortex Technology, Hadslund, Denmark), 
and perfusion by laser speckle contrast imaging (LSCI; 
PeriCam PSI System, Perimed Jäfälla, Sweden). TAP 
(FibroTx, Estonia) were used to quantify skin surface bio-
markers (IL-8, IFNα, IL-6, IL-10, CCL20, and HBD-2) by 
spot-enzyme-linked immunosorbent assay at predose and 
after end-of-treatment. Skin swabs were collected for mi-
crobiome analysis.
Three-millimeter punch biopsies were collected pre-
dose (after tape stripping) and at end-of-treatment. For all 
16 subjects, a biopsy of the VehO + VehI, IMQ + OMN1%, 
and IMQ + OMN2.5% treated areas was collected. For only 
eight subjects the IMQ + VehO-treated area was biopsied, 
to limit the number of biopsies per subject. Biopsies were 
snap frozen using liquid nitrogen and stored at -80°C until 
analysis at the Immunology Laboratory of Erasmus Medical 
Center, Rotterdam, The Netherlands, for determination of 
IFNα, IFNγ, IL-1β, IL-6, IL-8, HBD-2, MX1, MXA, CCL20, 
and IL-10 mRNA expression relative to the housekeeping 
gene ABL by quantitative polymerase chain reaction. In ad-
dition, all biopsies were hematoxylin-eosin stained to obtain 
histopathological scores of psoriasis and dermatitis; gen-
eral infiltration, parakeratosis, acanthosis, papillomatosis, 
Table 1 Treatment combinations
  Day 0 Day 1 Day 2 Day 3
1 Imiquimod Imiquimod Vehicle (omiganan) Vehicle (omiganan)
2 Imiquimod Imiquimod Omiganan 1% Omiganan 1%
3 Imiquimod Imiquimod Omiganan 2.5% Omiganan 2.5%
4 Vehicle (omiganan) Vehicle (omiganan) Vehicle (imiquimod) Vehicle (imiquimod)
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and spongiosis. The histopathological score for each char-
acteristic was graded based on fold increase or decrease 
compared with a reference biopsy of a healthy subject not 
participating in the clinical trial (1; equal to the reference 
biopsy, 2; twofold increase compared with the reference bi-
opsy, etc.). Furthermore, immunohistochemical staining was 
performed to obtain scoring of markers CD11c (Clone 5D11; 
Cell Marque), CD14 (Clone EPR3653; Cell Marque), CD1a 
(Clone EP3622; Cell Marque), CD4 (Clone SP35; Ventana), 
CD8 (Clone SP57; Ventana), and HLA-DR (CR3/43; Dako).
Safety end points
Safety and tolerability were monitored by tracking adverse 
events, performing physical examination, measuring vital 
signs, 12-lead electrocardiograms, and laboratory tests 
(i.e., hematology, chemistry, and urinalysis) at multiple time 
points throughout the study. IFNα, IFNβ, and IFNɣ were 
measured in blood samples to detect a possible systemic 
effect of the interventions.
Statistics
Treatment effects were analyzed with a mixed model analy-
sis of variance with the baseline measurement as covariate. 
To determine the differences between the treatments, 
contrasts were calculated for all measurements. All calcu-
lations were performed using SAS for windows version 9.4 
(SAS Institute, Cary, NC). Evaluation window for noninva-
sive measures was 0–96 hours (day 4), whereas biopsies 
were collected at 120 hours (day 5).
RESULTS
Twelve female (75%) and 4 male (25%) white subjects 
participated in the study. All 16 included subjects com-
pleted the study according to the schedule in Table 1. 
The mean age was 24.6 (SD ± 5.8 years). Application site 
pruritus was the most frequent occurring adverse event 
(AE) in 14 of 16 subjects (87.5%). This can be related to the 
tape-stripping procedure, occlusion procedure, or one of 
the treatments or vehicles. No serious AEs or discontin-
uations due to AEs occurred. No systemic effects of any 
of the treatments in terms of elevated circulating cyto-
kines (serum IFNα, IFN-β, or IFNɣ) were observed (data 
not shown).
IMQ treatment resulted in a modest inflammatory re-
sponse, observed as enhanced erythema (quantified by 
2D photograph; Figure 1, top panel) and perfusion (quan-
tified by LSCI; Figure 1, bottom panel). The maximal 
IMQ response was reached after 1–2  days of treatment 
(Figure 2). After 48  hours of VehI exposure, the target 
areas were treated with OMN (or vehicle) for an additional 
2 days. OMN treatment enhanced the IMQ-driven increase 
in skin perfusion and erythema, without an indication of 
OMN dose dependency (Figure 2). OMN treatment signifi-
cantly enhanced perfusion (profile 0–96 hours; Figure 2a: 
IMQ + vehicle vs. IMQ + OMN; +17.1%; 95% confidence 
interval (CI) 5.6%–30%; P  <  0.01 and  +  15.1%; 95% CI 
3.8%–27.7%; P  <  0.01 for 1% and 2.5% OMN, respec-
tively). For erythema, a statistically significant OMN effect 
was observed (profile 0–96  hours; for colorimetry, but 
only at the 1% OMN dose; Figure 2b: IMQ + vehicle vs. 
IMQ  +  OMN +1.5; 95% CI 0.25%–2.83%; P  =  0.02 and 
+0.92; 95% CI 0.37%–2.21%; P = 0.16 for 1% and 2.5% 
OMN, respectively). OMN treatment did not significantly 
alter IMQ-related increases in erythema index (profile 
0–96 hours; +0.8; 95% CI –1.62% to 3.25%; P = 0.51 and 
+2.21; 95% CI –0.23% to 4.64%; P  =  0.08 for 1% and 
2.5% OMN, respectively). The enhanced inflammatory re-
sponses were observed during the OMN treatment period 
(days 3 and 4; 48–96 hours). Hereafter, perfusion and ery-
thema returned within 1 day to levels as observed for the 
IMQ + vehicle treatment within 1 day (Figure 2; 120 hours).
In addition to the above noninvasive assessments, skin 
punch biopsies were taken from the target areas. Biopsies 
were stained for dermal immune cell infiltration, and in-
dependently analyzed by two investigators blinded to 
Figure 1 Clinical impression of imiquimod (IMQ) response (left panel) and IMQ + omiganan (OMN; middle and right panel) of one 
subject at day 4, 24 hours after the last application of omiganan or vehicle. VehO, omiganan vehicle.
IMQ+OMN2.5%IMQ+OMN1%IMQ+VehO
2D 
photography
Laser 
speckle 
contrast 
imaging 
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treatment compared with a reference biopsy (healthy unaf-
fected skin). IMQ treatment resulted in an influx of immune 
cells in the skin, reflected by an increase in macrophages, 
HLA-DR cells, myeloid dendritic cells, Langerhans cells, and 
CD4+ and CD8+ T cells (Figure 3a–f, second bars vs. first 
bars). Consistent with the observations for perfusion and 
erythema, OMN treatment enhanced the IMQ-driven inflam-
matory response as quantified in skin punch biopsies. When 
IMQ-exposed skin was treated with OMN, this resulted in a 
strong increase of infiltrating immune cells (Figure 3a–f, third 
and fourth bars vs. second bars). There was no indication of 
a clear OMN dose-dependency, although the response to 
the 1% OMN formulation seemed slightly higher.
Subsequently, the effects of IMQ and OMN add-on treat-
ment on local cytokine responses were investigated. As 
expected, IMQ treatment resulted in an NFκB-driven in-
crease in IL-6 and IL-10 (Figure 4a; IL-6 VehI vs. vehicle/
vehicle + 120.9%; 95% CI 2.6%–375.6%; P = 0.04; IL-10 
VehI vs. vehicle/vehicle + 132.1%; 95% CI 40.8%–282.8%; 
P = 0.001). In line with this, IMQ increased the expression of 
type I IFN-driven MXA (Figure 4b, left panel, VehI vs. vehicle/
vehicle + 213.3%; 95% CI 50.7%–551%; P = 0.002) and IFNɣ 
(Figure 4b right panel, VehI vs. vehicle/vehicle  +  542.4%; 
95% CI 132.1%–1678.3%; P < 0.001). No treatment effect 
was observed for MX1 expression. Subsequently, OMN was 
applied for 2 days to the target areas. Although OMN did not 
significantly alter any of the IMQ-driven responses, a higher 
level of cytokines was consistently found in the IMQ/OMN 
treatment group when compared with the VehI treatment 
group (Figure 4a; IL-6 and IL-10: for 1% OMN  +  26.3%; 
95% CI –41.6% to 173.1%; P = 0.55 and + 36.1%; 95% CI 
–17.7% to 125.1%; P = 0.23 for IL-6 and IL-10, respectively; 
Figure 4b: +88.4%; 95% CI –9.4% to 291.5%; P = 0.09 and 
+44.4%; 95% CI –48.1% to 302.4%; P = 0.48, for MXA and 
IFNɣ, respectively). Overall, the response induced by 1% 
OMN was more outspoken than the response to 2.5% OMN. 
IL-8 was induced by IMQ but no enhancement was seen 
with OMN addition (data not shown). No effects of IMQ and 
OMN add-on treatment were observed for the skin surface 
biomarkers by transdermal analysis patch, or on skin micro-
biome (data not shown).
DISCUSSION
In human peripheral blood mononuclear cells, OMN en-
hances inflammatory responses driven by endosomal 
TLRs (unpublished data, Grievink et al.). OMN strongly in-
creased type 1 IFN responses when cells were incubated 
with ligands for TLR3 (Poly:IC), TLR7 (IMQ), TLR8 (ssRNA), 
or TLR9 (CpG). IRF and NFκB pathways induced by these 
endosomal TLRs, drive tumoricidal and antiviral responses. 
Therefore, enhancement of endosomal TLR signaling in the 
skin may be of therapeutic interest for a variety of pathophys-
iological conditions. To investigate the clinical translation of 
Figure 2 Skin inflammation induced by imiquimod (IMQ) and omiganan (OMN), as quantified by laser speckle contrast imaging 
(perfusion/basal flow, a), and erythema assessments (b: colorimetry, c: erythema, d: visual grading). dLSM, delta least square mean; 
VehI, imiquimod vehicle; VehO, omiganan vehicle.
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OMN’s enhancement of endosomal TLR signaling, a healthy 
volunteer study was designed exploring the effects of IMQ 
combined with OMN add-on treatment. This combination 
was well-tolerated by the study participants, the main AE 
being mild application site pruritus, which was equal to the 
IMQ alone and OMN alone treatment groups. The clinical skin 
response was evaluated with LSCI (perfusion) and erythema 
assessments (colorimetry, erythema, and visual grading by 
the physician). Two days of IMQ treatment induced an in-
flammatory response similar as previously described,11 with 
erythema, increased perfusion, and increased inflammatory 
cell infiltration on histopathology lasting for at least 5 days. 
This effect was enhanced when IMQ was combined with 
OMN treatment. The influx of immune cells coincided with an 
increased cytokine response. IMQ induces an inflammatory 
response via TLR7-driven IRF and NFκB signaling,8 which 
plays a role in a variety of dermal cells (T cells, keratinocytes, 
macrophages, Langerhans cells, and dendritic cells). In this 
study, OMN treatment increased the IMQ-driven production 
of IL-6 and IL-10, reflecting NFκB activity. In addition, IRF-
driven pathways were enhanced: after application of OMN, 
elevated expression levels MXA were observed. MXA is a 
downstream mediator of interferons; its expression indicates 
an IFNα response.12 Moreover, OMN treatment increased 
type II interferon (IFNɣ) levels, which is mainly produced by 
T cells. Importantly, cellular and molecular responses were 
quantified in skin biopsies collected at day 5 (120  hours), 
where OMN (or vehicle) was applied at 0, 24, 48, and 72 hours. 
It could be contemplated that at earlier (uninvestigated) time 
points, the additive effect of OMN on immune responses was 
Figure 3 Skin inflammation induced by imiquimod (IMQ) and omiganan (OMN) on day 5 (scored compared with a reference biopsy), as 
quantified by immune cell influx. (a) CD14+ macrophages. (b) HLA-DR cells. (c) CD11c+ myeloid dendritic cells. (d) CD1a+ Langerhans 
cells. (e) CD4+ T cells. (f) CD8+ T cells. VehI, imiquimod vehicle; VehO, omiganan vehicle.
(a)
(c)
(e) (f)
(d)
(b)
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more outspoken, as observed for laser speckle and 2D pho-
tography data at time points 72–96 hours.
Our results relate to experimental conditions where skin of 
healthy human volunteers was first primed with IMQ, and sub-
sequently treated with OMN. The reverse sequence was also 
studied, with OMN pretreatment for 2 days followed by 2 day’s 
application of IMQ. With this treatment sequence, the enhanced 
effects of OMN on IMQ responses were not observed (data not 
shown). This is in line with mechanistic in vitro experiments 
on human peripheral blood mononuclear cells, which suggest 
that coinciding exposure to OMN and endosomal TLR ligands 
result in the strongest immune response (unpublished data, 
Grievink et al.). Furthermore, OMN treatment alone did not in-
duce any clinical, molecular, or cellular immune response (data 
not shown), which also corroborates with earlier peripheral 
blood mononuclear cell-based experiments. It is hypothesized 
that the immune enhancing effects of OMN on endosomal TLR 
signaling requires a complex formation between the cationic 
peptide and the TLR ligand. Such complex formation has been 
demonstrated earlier, for example, between TLR9 ligand CpG 
and the bovine host defense peptide indolicidin, thereby en-
hancing innate and adaptive immune responses.13
The potentiating effect of OMN on IMQ induced responses, 
and potentially on the effect of other endosomal TLR ligands 
that are currently under development as immunostimulatory 
compounds, may be interesting from a drug development per-
spective. The effectiveness of IMQ treatment for HPV-induced 
skin disease is suboptimal. In anogenital warts, for example, the 
estimated complete clearance is ~ 50%, with a recurrence rate 
of 13–19%. For HSIL, effectiveness of IMQ is estimated to be 
58% with a 16% recurrence rate.10,14–16 These data underline 
the need for enhanced treatment modalities. The combina-
tion treatment of IMQ with OMN may be considered as such. 
Although OMN’s effect size on top of IMQ-induced responses 
was relatively small in our study, and no clear dose-dependency 
for OMN was observed, our findings support the mechanistic 
Figure 4 Skin inflammation induced by imiquimod (IMQ), omiganan (OMN), vehicle imiquimod (VehI) and vehicle omiganan (VehO) on 
day 5, as quantified by cytokine production (quantitative polymerase chain reaction) relative to ABL. (a) IL-6 (left panel) and IL-10 (right 
panel). (b) MXA (left panel) and IFNɣ (right panel). N = 8 for the IMQ + VehO contrast and N = 16 for the other contrasts.
(a)
(b)
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concept of OMN-dependent enhancement of endosomal TLR 
signaling. Thus, optimization of combined OMN/IMQ treatment 
seems to be a rational way forward.
For practical reasons, IMQ and OMN could only be ad-
ministered as alternating treatments. Because a plausible 
mechanistic basis for OMN-enhanced IMQ effects is the 
complex formation between TLR ligand and cationic pep-
tide, it is not likely that pharmaceutical adjustments can be 
made to increase the desired effects. This may consist of 
optimization of the formulation containing a mixture of both 
compounds, or application of treatment regimens with rapid 
alternation of OMN and IMQ. Importantly, the observed en-
hanced IMQ responses by OMN co-treatment also support 
further exploration of treatments combining OMN with other 
endosomal TLR ligands. The limitation is that currently no 
other endosomal TLR ligands besides IMQ are available for 
clinical application in the European Union. Rintatolimod, a 
TLR3 ligand, is only accessible via an early access program 
for chronic fatigue syndrome. Other interesting candidates 
for combined treatment with OMN include resiquimod, a 
TLR7/8 agonist, or one of the TLR9 agonists that are cur-
rently being evaluated in phase III clinical programs.
In summary, OMN enhanced the inflammatory skin re-
sponse to IMQ, as studied in healthy volunteers with 
LSCI (perfusion), 2D photography (colorimetry, erythema, 
and visual grading), and analysis of molecular and cel-
lular responses in skin biopsies. Figure 5 provides a 
graphical summary of key biomarkers, and underlines the 
OMN-induced increase of IMQ-driven responses. These 
findings are in line with the observations of enhanced en-
dosomal TLR responses by OMN in in vitro experiments on 
primary human immune cells, and are supporting evaluation 
of IMQ/OMN combination therapy in HPV-induced skin dis-
eases, such as anogenital warts or HSIL.
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Figure 5 Graphical summary of key biomarkers: NF-κB-driven 
immune response (IL-6), IRF-driven immune response (MXA), 
perfusion (laser speckle contrast imaging (LSCI)), colorimetry 
(erythema), and immune cell infiltration (CD1a Langerhans cells). 
Responses were normalized to the maximal effects. Category 
labels indicate the actual minimum and maximum response. 
IMQ, imiquimod; OMI, omiganan; VehI, imiquimod vehicle; VehO, 
omiganan vehicle.
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